Macular Degeneration News and Research RSS Feed - Macular Degeneration News and Research

Macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.
Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [More]
Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME. [More]
Loyola ophthalmologist recommends specific foods and supplements for healthy vision

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

You may remember your mother telling you to eat your carrots; they are good for your eyes. Well, she was right. "Carrots are actually just one of the many foods, and supplements that contribute to good eye health," says James McDonnell, MD, pediatric ophthalmologist, Loyola University Health System. "In some cases, eyesight can actually be improved depending on what you eat." [More]
Medicine-loaded nanoparticles could help patients achieve corneal transplant success

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
UTSA professor named Gold Fellow of the Association for Research in Vision and Ophthamology

UTSA professor named Gold Fellow of the Association for Research in Vision and Ophthamology

Andrew Tsin, professor of biology in the UTSA College of Sciences, has been named a Gold Fellow of the Association for Research in Vision and Ophthamology for his dedication and exemplary contributions in the field. Tsin will receive the honor at the 2015 ARVO Annual Meeting, May 3-7 in Denver. [More]
Simple training can improve vision in older adults

Simple training can improve vision in older adults

Just a weeks' worth of training can improve vision in older adults, according to new research in Psychological Science, a journal of the Association for Psychological Science. The findings show that training boosted older adults' sensitivity to contrast and also their ability to see things clearly at close distances. [More]
Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung. [More]
Researchers discover retina protein crucial for vision

Researchers discover retina protein crucial for vision

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
MIT chemical engineers develop new type of self-healing hydrogel

MIT chemical engineers develop new type of self-healing hydrogel

Scientists are interested in using gels to deliver drugs because they can be molded into specific shapes and designed to release their payload over a specified time period. However, current versions aren't always practical because must be implanted surgically. [More]
Omega-3 could supplement anti-VEGF treatment in AMD

Omega-3 could supplement anti-VEGF treatment in AMD

Pilot study findings suggest that taking omega-3 fatty acid supplements could increase the efficacy or reduce the needed frequency of anti-vascular endothelial growth factor treatment in patients with exudative age-related macular degeneration. [More]

‘Earliest’ characteristics presaging drusen-associated atrophy identified

Researchers have used spectral-domain optical coherence tomography to identify specific pathological changes that precede the development of drusen-associated atrophy in patients with age-related macular degeneration. [More]

Adaptive optics find reflectivity differences between drusen types in AMD

Adaptive optics provide insight into the differences in reflectivity between medium–large drusen and reticular pseudodrusen in patients with age-related macular degeneration, researchers report. [More]

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology. [More]

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma. [More]
First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

ChromaDex Corp. announced today that the initial results of the first human clinical study for the company's NIAGEN nicotinamide riboside (NR) has met its primary endpoint. [More]
NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

Macular degeneration is a major cause of irreversible vision loss in the United States and around the world. As many as 11 million Americans have some form of macular degeneration. [More]
New study shows that 25% of homeless people in Toronto have vision problems

New study shows that 25% of homeless people in Toronto have vision problems

Twenty-five per cent of homeless people surveyed in Toronto had vision problems up to and including blindness, four times higher than the rate of the overall population in North America, a new study by St. Michael's Hospital has found. [More]
EyePromise® eye vitamins offers education guide to promote awareness on AMD

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020. [More]
Advertisement
Advertisement